A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).
Clinical trial NCT05141786 · UNKNOWN
Trial details
- NCT number
- NCT05141786
- Sponsor
- Shanghai Miracogen Inc.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-12-01
- Primary completion
- 2023-12-01
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.